Drug Design

Kenneth M. Merz received his PhD in organic chemistry at the University of Texas at Austin and completed postdoctoral research at Cornell University and the University of California, San Francisco. He is a member of the Quantum Theory Project and Professor of Chemistry at the University of Florida, Gainesville. Dagmar Ringe received her PhD in biochemistry at Boston University. She is Professor of Biochemistry and Chemistry in the Rosenstiel Basic Medical Sciences Research Center at Brandeis University, Waltham, Massachusetts. Charles H. Reynolds received his PhD in theoretical organic chemistry at the University of Texas, Austin. He is a Research Fellow at Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania.

Preface; 1. Progress and issues for computationally guided lead discovery and optimization William L. Jorgensen; Part I. Structural biology: 2. X-ray crystallography in the service of structure-based drug design Gregory A. Petsko and Dagmar Ringe; 3. Fragment-based structure-guided drug discovery: strategy, process, and lessons from human protein kinases Stephen K. Burley, Gavin Hirst, Paul Sprengeler and Siegfried Reich; 4. NMR in fragment-based drug discovery Christopher A. Lepre, Peter J. Connolly and Jonathan M. Moore; Part II. Computational Chemistry Methodology: 5. Free-energy calculations in structure-based drug design Michael R. Shirts, David L. Mobley and Scott P. Brown; 6. Studies of drug resistance and the dynamic behavior of HIV-1 protease through molecular dynamics simulations Fangyu Ding and Carlos Simmerling; 7. Docking: a domesday report Martha S. Head; 8. The role of quantum mechanics in structure-based drug design Kenneth M. Merz; 9. Pharmacophore methods Steven L. Dixon; 10. QSAR in drug discovery Alexander Tropsha; 11. Predicting ADME properties in drug discovery William J. Egan; Part III. Applications to drug discovery: 12. Computer-aided drug design: a practical guide to protein-structure-based modeling Charles H. Reynolds; 13. Structure-based drug design case study: p38 Arthur M. Doweyko; 14. Structure-based design of novel P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease M. Katharine Holloway and Nigel J. Liverton; 15. Purine nucleoside phosphorylases as targets for transition-state analog design Andrew S. Murkin and Vern L. Schramm; 16. GPCR 3D modeling Frank U. Axe; 17. Structure-based design of potent glycogen phosphorylase inhibitors Qiaolin Deng.